Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 16, 2023 - Issue
Submit an article Journal homepage
321
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

Jorge F Maspero1 Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, ArgentinaCorrespondence[email protected]
View further author information
,
Claus Bachert2 Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium;3 Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, SwedenView further author information
,
Fernando J Martinez4 Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2412-3182View further author information
ORCID Icon,
Nicola A Hanania5 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USAView further author information
,
Benjamin Ortiz6 Immunology and Allergy Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
,
Naimish Patel7 Immunology and Inflammation, Sanofi, Cambridge, MA, USAView further author information
,
Leda P Mannent8 Global Clinical Development, Sanofi, Chilly-Mazarin, FranceView further author information
,
Amy Praestgaard7 Immunology and Inflammation, Sanofi, Cambridge, MA, USAView further author information
,
Nami Pandit-Abid9 Immunology and Inflammation, Sanofi, Bridgewater, NJ, USAView further author information
,
Shahid Siddiqui6 Immunology and Allergy Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAORCID Iconhttps://orcid.org/0000-0001-9726-9003View further author information
ORCID Icon &
Megan Hardin7 Immunology and Inflammation, Sanofi, Cambridge, MA, USAView further author information
 show all
Pages 333-342 | Received 07 Jan 2022, Accepted 17 May 2022, Published online: 31 Mar 2023

Figures & data

Table 1 Breakdown of the Criteria for Clinical Features of Obstructive Lung Disease

Table 2 Demographic and Baseline Characteristics of Subgroups of Patients with CRSwNP from SINUS-24 and SINUS-52 with a Diagnosis of Asthma or with Clinical Features of Obstructive Lung Disease

Figure 1 Effect of dupilumab on NPS in patients with CRSwNP and clinical features of obstructive lung disease.

Notes: Data are LS mean change (± SE) from baseline in NPS (range 0–8) in patients with CRSwNP and clinical features of obstructive lung disease (broad definition, A; narrow definition, B), or diagnosis of asthma (C). Nominal p vs placebo ***<0.001.
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; LS, least squares; NPS, nasal polyp score; q2w, every 2 weeks; SE, standard error.
Figure 1 Effect of dupilumab on NPS in patients with CRSwNP and clinical features of obstructive lung disease.

Figure 2 Effect of dupilumab on UPSIT score in patients with CRSwNP and clinical features of obstructive lung disease.

Notes: Data are LS mean change (± SE) from baseline in UPSIT (range 0–40) in patients with CRSwNP and clinical features of obstructive lung disease (broad definition, A; narrow definition, B), or diagnosis of asthma (C). Nominal p vs placebo ***<0.001.
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; LS, least squares; q2w, every 2 weeks; SE, standard error; UPSIT, University of Pennsylvania Smell Identification Test.
Figure 2 Effect of dupilumab on UPSIT score in patients with CRSwNP and clinical features of obstructive lung disease.

Figure 3 Effect of dupilumab on SNOT-22 total score in patients with CRSwNP and clinical features of obstructive lung disease.

Notes: Data are LS mean change (± SE) from baseline in SNOT-22 (range 0–110) in patients with CRSwNP and clinical features of obstructive lung disease (broad definition, A; narrow definition, B), or diagnosis of asthma (C). Nominal p vs placebo **<0.01, ***<0.001.
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; LS, least squares; q2w, every 2 weeks; SE, standard error; SNOT-22, 22-item Sino Nasal Outcome Test.
Figure 3 Effect of dupilumab on SNOT-22 total score in patients with CRSwNP and clinical features of obstructive lung disease.

Figure 4 Effect of dupilumab on lung function in patients with CRSwNP and clinical features of obstructive lung disease.

Notes: Data are LS mean change (± SE) from baseline in pre-bronchodilator FEV1 (A–C) and pre-bronchodilator FEV1/FVC ratio (D–F) in patients with CRSwNP with diagnosis of asthma and clinical features of obstructive lung disease (broad definition, A and D; narrow definition, B and E), or diagnosis of asthma (C and F). †Pre-specified p vs placebo <0.001. Nominal p vs placebo *<0.05, **<0.01, ***<0.001.
Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LS, least squares; q2w, every 2 weeks; SE, standard error.
Figure 4 Effect of dupilumab on lung function in patients with CRSwNP and clinical features of obstructive lung disease.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.